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Abstract
The viral reservoir represents a critical challenge facing HIV-1 eradication strategies1–5. However,
it remains unclear when and where the viral reservoir is seeded during acute infection and the
extent to which it is susceptible to early antiretroviral therapy (ART). Here we show that the viral
reservoir is seeded very early following mucosal SIV infection of rhesus monkeys and prior to
systemic viremia. We initiated suppressive ART in groups of monkeys on days 3, 7, 10, and 14
following intrarectal SIVmac251 infection. Treatment on day 3 blocked the emergence of viral
RNA and proviral DNA in peripheral blood and also substantially reduced levels of proviral DNA
in lymph nodes and gastrointestinal mucosa as compared with treatment at later timepoints. In
addition, treatment on day 3 abrogated the induction of SIV-specific humoral and cellular immune
responses. Nevertheless, following discontinuation of ART after 24 weeks of fully suppressive
therapy, virus rebounded in all animals, although animals treated on day 3 exhibited a delayed
viral rebound as compared with animals treated on days 7, 10 and 14. The time to viral rebound
correlated with total viremia during acute infection and with proviral DNA at the time of ART
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discontinuation. These data demonstrate that the viral reservoir is seeded very early following
intrarectal SIV infection of rhesus monkeys, during the “eclipse” phase, and prior to viremia. This
strikingly early seeding of the refractory viral reservoir raises important new challenges for HIV-1
eradication strategies.
The viral reservoir in memory CD4+ T cells in HIV-1-infected individuals cannot be
eliminated by current antiretroviral drugs or HIV-1-specific immune responses1–5. This
archive of replication-competent virus is the source of viral rebound in nearly all HIV-1-
infected individuals who discontinue ART3,5 and represents a critical hurdle for HIV-1
eradication strategies6,7. The temporal dynamics of seeding the viral reservoir has not
previously been defined but has been presumed to occur during peak viremia in acute HIV-1
infection. To evaluate the impact of early ART on the viral reservoir, we initiated
suppressive ART at various timepoints following mucosal SIV infection of rhesus monkeys.
We inoculated 20 Indian origin adult rhesus monkeys (Macaca mulatta) that did not express
the protective MHC class I alleles Mamu-A*01, Mamu-B*08, and Mamu-B*17 with 500
TCID50 SIVmac2518–10 by the intrarectal route. We initiated ART on days 3, 7, 10, and 14
following infection with a pre-formulated cocktail of tenofovir, emtricitabine, and
dolutegravir (see Methods), and a control group received no ART (n=4/group). ART was
administered daily by subcutaneous injection for 24 weeks. Treatment on day 3 following
infection resulted in no detectable viremia (<50 RNA copies/ml)11 at any timepoint in 4 of 4
monkeys (Fig. 1a). In contrast, treatment on days 7, 10, and 14 abruptly interrupted the
exponential growth of the virus and reduced plasma viral RNA to undetectable levels within
3–4 weeks. The mean levels of plasma viral RNA at the time of ART initiation in these
groups of monkeys were 5.88 log copies/ml (day 7), 7.11 log copies/ml (day 10), and 7.50
log copies/ml (day 14), which were comparable with the levels of plasma viral RNA in
untreated controls at these timepoints (Fig. 1b). Viral dynamics modeling12 revealed an
initial exponential growth rate of 1.5 ± 0.5 per day, corresponding to a basic reproductive
ratio of R0 = 9.5 ± 5.1 (see Methods; Extended Data Fig. 1; Extended Data Table 1). An
exponential decay rate of plasma viremia following ART initiation of 0.60 ± 0.17 per day
was observed in all the treated groups, corresponding to a 1.3 ± 0.4 day half-life of infected
cells (Extended Data Fig. 1).
Following initial control of viremia, all animals treated with ART exhibited undetectable
plasma viral loads (<50 RNA copies/ml) for the full 24 week course of suppressive therapy
with no detectable viral blips (Fig. 1a), demonstrating the potency and consistency of this
ART regimen. Moreover, ultrasensitive plasma viral load assays at week 20 also proved
negative (<6 RNA copies/ml)13 in all animals (Extended Data Fig. 2). In addition, viral
sequences from stimulated PBMC from ART suppressed, SIV-infected monkeys using the
same ART regimen revealed no viral sequence evolution over 6 months in a separate study
(J.B.W., unpublished data). Furthermore, treatment intensification studies in SIV-infected
rhesus monkeys in which the protease inhibitor darunavir was added to the current ART
regimen did not lead to improved virologic control (R.G., unpublished data). Taken together,
these data suggest that the ART regimen that was utilized in the present study was fully
suppressive.
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We next assessed the development of SIV-specific humoral and cellular immune responses
in these animals. Animals treated on day 3 following infection developed no detectable SIV
Env-specific antibody responses by ELISA (Fig. 2a) and no detectable SIV Env-, Pol-, or
Gag-specific T lymphocyte responses by IFN-γ ELISPOT assays (Fig. 2b) at weeks 4, 10,
and 20 or 24 of infection. In contrast, animals treated on days 7, 10, and 14 developed
detectable but lower SIV-specific humoral and cellular immune responses as compared with
untreated controls, presumably as a result of reduced antigenic stimulus following ART
initiation. Multiparameter intracellular cytokine staining (ICS) assays confirmed that SIV
Gag-specific CD8+ and CD4+ T lymphocyte responses were undetectable in animals treated
on day 3 and were lower in animals treated on days 7, 10, and 14 as compared with
untreated controls (Extended Data Figs. 3–4). Gag-specific CD8+ and CD4+ T lymphocytes
in animals treated on days 7, 10, and 14 also exhibited reduced immune activation and
proliferation as measured by Ki67 expression as compared with untreated controls
(Extended Data Fig. 4). These data demonstrate that initiation of ART on day 3 blocked the
emergence of plasma viremia and abrogated the induction of SIV-specific humoral and
cellular immune responses.
We next determined the impact of early ART on levels of proviral DNA14 in peripheral
blood mononuclear cells (PBMC), lymph node mononuclear cells (LNMC), and
gastrointestinal mucosa mononuclear cells (GMMC) over the course of 24 weeks of
treatment with suppressive ART. In animals that initiated ART on day 3, there was a striking
anatomic discordance with no proviral DNA detected in PBMC at any timepoint (<3 DNA
copies/106 cells) (Fig. 3a). In contrast, clear but low levels of proviral DNA were detected in
inguinal LNMC and in colorectal GMMC in these animals, although proviral DNA declined
to undetectable or nearly undetectable levels in 3 of 4 of these animals by week 24. In
monkeys treated with ART on days 7, 10, and 14, proviral DNA was readily detected in
PBMC as well as in LNMC and GMMC (Fig. 3b–d). Moreover, in animals treated with
ART on days 10 and 14, proviral DNA in LNMC appeared to stabilize by week 12 with
minimal subsequent decline, consistent with a stable viral reservoir (Fig. 3c–d). In untreated
animals, proviral DNA was markedly higher than in ART treated animals with minimal
decline (Fig. 3e). Analysis of sorted cell subpopulations demonstrated that proviral DNA
was found primarily in central memory and transitional memory CD4+ T lymphocytes in
lymph nodes on day 3 and in both PBMC and lymph nodes on day 7 following SIV infection
(Extended Data Fig. 5).
These data indicate that initiation of ART on day 3 reduced levels of proviral DNA at week
24 by at least 2.2 logs in PBMC (P<0.0001; Fig. 3f), 1.0 log in LNMC (P=0.004; Fig. 3g),
and 0.9 log in GMMC (P=NS; Fig. 3h) as compared with initiation of ART on day 14. The
high variability in the GMMC samples likely reflected sampling variation in this anatomic
compartment. Compared to untreated animals, initiation of ART on day 3 reduced levels of
proviral DNA at week 24 by at least 3.3 logs in PBMC (P<0.0001; Fig. 3f) and 3.1 logs in
LNMC (P<0.0001; Fig. 3g).
At week 24, ART was discontinued, and animals were monitored twice weekly for evidence
of viral rebound. Viral rebound, defined as plasma viral RNA >50 copies/ml, occurred in all
animals (Fig. 4a). In particular, viral rebound occurred in 4 of 4 animals that initiated ART
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on day 3, albeit with 3-fold delayed kinetics as compared with animals that initiated ART at
later timepoints (median 21 days to viral rebound in the day 3 treated animals compared
with 7 days in the day 14 treated animals; P<0.001; Fig. 4b). The median log setpoint viral
load following rebound, defined as viral loads on days 56–112 following ART
discontinuation, was also 1.04 log RNA copies/ml lower for all the ART treated animals as
compared with untreated controls (4.59 log RNA copies/ml for all treatment groups
combined vs. 5.63 log RNA copies/ml for untreated animals; P=0.01; Fig. 4c), suggesting a
benefit to early ART, although no significant differences were observed among setpoint
viral loads in the day 3, 7, 10, and 14 treatment groups. Setpoint viral loads in the untreated
animals were comparable with historical controls9,10. Taken together, these data show that
the persistent viral reservoir was seeded by day 3 of infection and led to viral rebound in all
animals following ART discontinuation.
To gain mechanistic insight into the kinetics of the viral rebound, we utilized viral dynamics
modeling15,16 (see Methods; Extended Data Fig. 6; Extended Data Table 2). Initiation of
ART on day 3 as compared with days 7, 10, and 14 resulted in lower modeled residual viral
loads at the time of ART discontinuation (P=0.01) and a trend towards a greater viral growth
rate R0 during viral rebound (P=0.06), but no difference in post-rebound setpoint viral loads
(Extended Data Fig. 7). Average R0 during viral rebound was 4.2 ± 1.8 in the day 3 treated
animals as compared with 2.3 ± 0.6 in the day 14 treated animals (P=0.05; Extended Data
Fig. 7), presumably reflecting the partially effective SIV-specific immune responses in the
latter group (Fig. 2). Total plasma viremia during acute infection was interpolated and
calculated as the area under the curve for pre-ART viral loads (AUC VL) (Extended Data
Fig. 8). Consistent with recent findings in acute HIV-1 infection in humans16, the AUC VL
during acute infection correlated with levels of proviral DNA in PBMC (P<0.0001; Fig. 5a),
LNMC (P=0.005; Fig. 5b), and GMMC (P=0.04; data not shown) at the time of ART
discontinuation. Moreover, both the AUC VL (P<0.0001; Fig. 5c) and proviral DNA in
PBMC at the time of ART discontinuation (P=0.003; Fig. 5d) correlated inversely with the
interpolated time to viral rebound. These data suggest that total plasma viremia during acute
infection and proviral DNA immediately prior to ART discontinuation may predict the time
to viral recrudescence.
In this study, we show that the viral reservoir can be seeded substantially earlier than
previously recognized. Following intrarectal SIV infection of rhesus monkeys, the viral
reservoir was seeded during the first few days of infection, during the “eclipse phase”, and
prior to detectable viremia, probably in the mucosal and lymphoid tissues that represent the
first sites of viral replication17. Consistent with this finding, we observed proviral DNA in
lymph nodes and in gastrointestinal mucosa but not in PBMC in animals treated on day 3
following infection (Fig. 3a; Extended Data Fig. 5). The observation that the viral reservoir
can be seeded prior to detectable viremia suggests that substantial pathogenesis occurs in
tissues in the first few days following mucosal virus exposure and prior to virus replication
in peripheral blood, which has important implications for HIV-1 therapeutics and
eradication strategies.
Our data are concordant with recent clinical studies that have demonstrated that early ART
can reduce the size of the viral reservoir and delay or reduce viral rebound following ART
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discontinuation in humans18–22. Our findings similarly show that early ART decreased
proviral DNA in blood and tissues (Fig. 3f–h) and both delayed and reduced viral rebound
(Fig. 4b–c) following ART discontinuation in SIV-infected rhesus monkeys. Moreover, our
observations extend prior studies that have shown effective post-exposure prophylaxis with
short courses of ART when initiated 24 hours following SIV infection in monkeys23,24.
However, in the present study, initiation of suppressive ART even as early as day 3 of
infection failed to eliminate the viral reservoir and did not prevent viral rebound despite 24
weeks of effective therapy. In addition, our data (Fig. 4a) are consistent with clinical studies
that have shown that the vast majority HIV-1-infected individuals who initiate ART during
acute infection show viral rebound following discontinuation of ART25–27.
Our findings contrast with the sustained remission and potential cure of a viremic baby that
was treated with ART at 31 hours of life28. It is possible that this baby was inoculated
parenterally with maternal cells instead of mucosally with virus, resulting in rapid viremia
without a previremic eclipse phase of viral replication in mucosal and lymphoid tissues. The
positive outcome in this baby might therefore have reflected the route of transmission, the
lack of an eclipse phase in tissues, the very rapid initiation of ART, and/or the paucity of
memory CD4+ T lymphocytes in the neonatal immune system29.
Clinical studies are required to confirm our observations, since important differences exist
between SIV infection of rhesus monkeys and HIV-1 infection of humans. For example, the
SIV dose used in the present study in monkeys was selected to limit the number of
transmitted/founder viruses but also to infect all animals8 and thus was substantially higher
than typical HIV-1 doses in humans. Nevertheless, the higher challenge dose has been
shown to shorten the eclipse period and to lead to earlier plasma viremia8. Additional
virologic and immunologic differences may also exist between SIV-infected rhesus
monkeys and HIV-1-infected humans.
The strikingly early seeding of the viral reservoir within the first few days of infection is
sobering and presents new challenges to HIV-1 eradication efforts. If HIV-1 similarly seeds
a persistent viral reservoir in mucosal and lymphoid tissues during the eclipse phase of
infection and prior to viremia following sexual exposures in humans, then it will be very
difficult to initiate ART prior to reservoir seeding, since viremia is typically utilized for the
clinical diagnosis of acute HIV-1 infection. Taken together, our data suggest that extremely
early initiation of ART, extended ART duration for years, and most likely additional
interventions that activate the viral reservoir will be required for HIV-1 eradication.
Moreover, an improved understanding of the virologic parameters that predict viral rebound
following ART discontinuation will help guide future HIV-1 eradication efforts.
Methods
Animals
20 outbred, Indian-origin, young adult, male and female rhesus monkeys (Macaca mulatta)
were genotyped and selected as negative for the protective MHC class I alleles Mamu-A*01,
Mamu-B*08, and Mamu-B*17. Animals expressing susceptible and resistant TRIM5α
alleles were distributed amongst the groups. Animals were otherwise randomly allocated to
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groups. All monkeys were housed at Bioqual, Rockville, MD. Animals were infected with
500 TCID50 of our SIVmac251 challenge stock8–10 by the intrarectal route. Monkeys were
bled up to two times per week for viral load determinations. Assays were performed blinded.
All animal studies were approved by the appropriate Institutional Animal Care and Use
Committee (IACUC).
ART regimen
The pre-formulated antiretroviral therapy (ART) cocktail contained two reverse transcriptase
inhibitors, 20 mg/mL tenofovir (TFV) and 50 mg/mL emtricitabine (FTC) plus 2.5 mg/mL
of the integrase inhibitor dolutegravir (DTG) in a solvent containing 25% (v/v) polyethylene
glycol 400 (PEG-400), 15% (w/v) captisol and 0.075 N sodium hydroxide (NaOH) in water.
This ART cocktail was administered once daily at 1 mL/kg body weight via the
subcutaneous route. The cocktail was prepared by mixing DTG stock solution (10 mg/mL of
DTG in PEG-400), TFV and FTC stock solution (80 mg/mL of TFV and 200 mg/mL of FTC
in 0.3 N NaOH), and 30% (w/w) captisol solution at a 1:1:2 (v:v:v) ratio. The final solution
was clear and at pH ~6. It was sterile filtered, aliquoted into sterile glass vials in a biosafety
cabinet, and frozen at −20°C until used.
Cellular immune assays
SIV-specific cellular immune responses were assessed by IFN-γ ELISPOT assays and
multiparameter ICS assays essentially as previously described9. 12-color ICS assays were
performed with the Aqua green-fluorescent reactive dye (Invitrogen, L23101) and
predetermined titers of mAbs (Becton-Dickinson) against CD3 (SP34; Alexa Fluor 700),
CD4 (OKT4; BV711, Biolegend), CD8 (SK1; allophycocyanin-cyanine 7 [APC-Cy7]),
CD28 (L293; BV610), CD95 (DX2; allophycocyanin [APC]), CD69 (TP1.55.3;
phycoerythrin-Texas red [energy-coupled dye; ECD]; Beckman Coulter), gamma interferon
(IFN-γ) (B27; phycoerythrin-cyanine 7 [PE-Cy7]), Ki67 (B56; fluorescein isothiocyanate
[FITC]), CCR5 (3A9; phycoerythrin [PE]), CCR7(3D12; Pacific Blue), and PD-1(EH21.1;
peridinin chlorophyll-A-cyanine 5.5 [PerCP-Cy5.5]). IFN-γ backgrounds were consistently
<0.01% in PBMC.
Humoral immune assays
SIV Env-specific antibody responses were assessed by a direct ELISA essentially as
previously described9.
Viral RNA assays
Viral RNA was isolated from cell-free plasma using a viral RNA extraction kit (Qiagen) and
was quantitated essentially as previously described11. RNA was isolated by phenol-
chloroform purification followed by ethanol precipitation. All purified RNA preparations
were quantified by optical density. Quantitative RT-PCR was conducted in a 2-step process.
First, RNA was reverse transcribed in parallel with an SIV-gag RNA standard using the
gene-specific primer sGag-R 5′CACTAGGTGTCTCTGCACTATCTGTTTTG-3′. All
samples were then treated with RNAse H (Stratagene) for 20 minutes at 37°C. Primer
sequences were adapted from those described11 including the forward primer s-Gag-F: 5′-P:
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5′-CTTCCTCAGTGTGTTTCACTTTCTCTTCTGCG-3′, linked to Fam and BHQ
(Invitrogen, Carlsbad, CA). All reactions were carried out on a 7300 ABI Real-Time PCR
system (Applied Biosystems) in triplicate according to the manufacturer’s protocols.
Ultrasensitive viral load assays were performed essentially as described13.
Proviral DNA assays
Lymph node and gastrointestinal mucosal biopsies were processed as single cell
suspensions, and levels of tissue-specific proviral DNA were quantitated as previously
described14. Total cellular DNA was isolated from 5x106 cells using a QIAamp DNA Blood
Mini kit (Qiagen). The absolute quantification of viral DNA in each sample was determined
by qPCR using primers specific to a conserved region SIVmac239. All samples were
directly compared to a linear virus standard and the simultaneous amplification of a
fragment of human GAPDH gene. The sensitivity of linear standards was compared against
the 3D8 cell line as a reference standard as described14. PCR assays were performed with
100–200 ng sample DNA.
Viral dynamics modeling and statistical analyses
Plasma viral load levels pre-treatment, during treatment, and following treatment
interruption were fit to a viral dynamics model to determine key parameters12. In order to
derive individual level estimates with limited data points for each animal, we used a
simplified version of the full system of differential equations describing the viral dynamics
model, which had fewer parameters and could be solved analytically. All fits were evaluated
using the nlinfit function in the MATLAB Statistical Toolbox. For acute infection in all
animals treated on days 7, 10 or 14, and for rebound in all animals, data points below the
limit of detection were treated as missing data (except for the last undetectable value after
infection or interruption, which we took to equal the detection limit of 50 copies/ml).
Treating undetectable viral load values as left-censored data using a maximum likelihood
approach did not noticeably change the results.
Pre-treatment and during treatment—We fit the viral dynamics observed following
infection and treatment up to week 24 using a three-parameter piecewise function:
(1)
where tART, the time that treatment was started, was defined based on the cohort as 3, 7, 10,
or 14 days. Here v0 is the effective infectious viral load from which the infection starts
(v(0)), a is the growth rate of viral load during acute infection, and d is the decay rate of
viral load once treatment is started (if treatment is effective, the lifespan of infected cells is
approximately 1/d). In essence, the model allows viral load to increase exponentially until
treatment begins, and then decrease exponentially until it is below the detection limit. This
approximates the observed dynamics well because a stable setpoint was not reached prior to
treatment, and insufficient data points above the detection limit existed during viral decay to
observe biphasic behavior.
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The basic reproductive ratio of the infection, defined as the average number of new infected
cells produced by a single infected cell during early infection, can be calculated from these
parameters as R0 = a/d +1. However, others have reported12 that due to the intracellular
delay between infection and the production of virus, this formula underestimates R0. To
correct for this effect, we use a modified expression, R0 = (a/d +1)(ap +1), where p is the
average length of the delay (which we take to be 1 day).
The area-under-the-curve of viral loads (AUC VL) was used as a measure of the total
number of cells infected15,16. The AUC VL was used as a measure of the total amount of
infections occurring, which is a reasonable approximation for acute SIV infection since
CD4+ T cell levels do not change consistently or significantly. We assumed that ART was
fully effective so that there were no new infections following ART initiation, leading to the
following formula:
(2)
No fits were conducted for animals treated after 3 days, since all observed viral load values
were below the limit of detection. To estimate AUC VL for these, we used the average
values of v0 and a from the remaining 12 animals in the above formula with tART = 3.
Following ART discontinuation—We fit the viral dynamics observed following ART
discontinuation (starting at week 24) using a separate three-parameter function:
(3)
Here t is the time since interruption. The parameter vr is the infectious residual viral load
from which the infection starts (v(0)), r is the growth rate of viral load during rebound, and
vmax is the viral setpoint reached after rebound. This logistic equation is an approximation to
the full viral dynamics model that smooths out both high frequency fluctuations in viral load
and lags in uninfected CD4+ T cell dynamics (such as overshooting the setpoint)15. Using
these fits, we can interpolate the time at which viral load crossed the threshold of 50
copies/ml to define the rebound time. Similar to pre-treatment, we can calculate the post-
rebound basic reproductive ratio as R0 = (r/d +1)(a p +1), where d is the viral decay
measured during treatment and p is the average length of the intracellular delay between
infection and virion production which is assumed to be exponentially distributed (and which
we take to be 1 day).
Statistics—All comparisons between cohorts were done using unpaired, equal variance,
one-tailed t-tests. Correlation analysis was carried out in using the MATLAB corrcoef
function (Pearson correlation). The standardized major axis method was employed for
regression analysis (also known as “geometric mean regression” or “reduced major axis
regression”), using the gmregress function for the MATLAB Statistical Toolbox (available
at http://www.mathworks.com/matlabcentral/fileexchange/27918-gmregress).
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Extended Data
Extended Data Figure 1.
Viral dynamics modeling of initial viral growth and decay following ART initiation.
Red lines indicate fitted values from the model in monkeys that initiated ART on days 3, 7,
10, and 14 of infection and were utilized for AUC VL calculations. The red asterisk
indicates the time of treatment initiation.
Extended Data Figure 2.
Ultrasensitive plasma viral loads in monkeys during ART.
Log plasma viral RNA (copies/ml) at week 20 in rhesus monkeys infected with SIVmac251
and following initiation of ART on days 3, 7, 10, and 14 of infection. Assay sensitivity is 6
RNA copies/ml.
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Extended Data Figure 3.
Intracellular cytokine staining raw data of Gag-specific CD8+ and CD4+ T cells.
Representative data for the magnitude of Gag-specific IFN-γ+ CD8+ and CD4+ T cell
responses at week 20 in monkeys that initiated ART on days 3, 7, 10, and 14 of infection or
with no ART.
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Extended Data Figure 4.
Intracellular cytokine staining of Gag-specific CD8+ and CD4+ T cells.
Summary data for the magnitude of Gag-specific IFN-γ+ CD8+ and CD4+ T cell responses
and Ki67 expression at week 4 and week 20 in monkeys that initiated ART on days 3, 7, 10,
and 14 of infection or with no ART (N=4 animals per group).
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Extended Data Figure 5.
Proviral DNA in CD4+ T cell subpopulations during ART.
Log proviral DNA (copies/106 CD4 T cells) in sorted naïve (N), transitional effector
memory (TM), and central memory (CM) CD4 T cell subpopulations from PBMC and from
genital, inguinal, iliac, para-aortic, axillary, and/or mesenteric lymph nodes obtained from
two animals necropsied on day 3 and two animals necropsied on day 7 following mucosal
SIVmac251 infection.
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Extended Data Figure 6.
Viral dynamics modeling of viral rebound following ART discontinuation.
Red lines indicate fitted values from the model in monkeys that initiated ART on days 3, 7,
10, and 14 of infection.
Extended Data Figure 7.
Viral kinetics and setpoint viral loads following ART discontinuation.
Log initial viral loads, exponential viral growth rate, and log setpoint viral loads following
viral rebound derived from the model fits in groups of monkeys that initiated ART on days
3, 7, 10, and 14 of infection (N=4 animals per group).
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Extended Data Figure 8.
Early ART impacts AUC VL and time to viral rebound.
Log AUC VL and interpolated time of viral rebound derived from the model fits are shown
in monkeys that initiated ART on days 3, 7, 10, and 14 of infection (N=4 animals per
group).
Extended Data Table 1
Best-fit parameters for viral dynamics pre-ART and during ART.
Fitted parameters include v0, the effective infectious viral load from which the infection
starts, a, the growth rate of viral load during acute infection, and d, the decay rate of viral
load once treatment is started. See the Methods section, including Equations 1 and 2, for
detailed descriptions.
Fitted parameters Derived parameters
Days until ART started log10(v0) a d Half-life (In(2)/d) R0 log10(AUC)
3 - - - - - 2.6
3 - - - - - 2.6
3 - - - - - 2.6
3 - - - - - 2.6
7 −1.16 2.19 0.50 1.38 17.10 5.1
7 1.44 1.45 0.29 2.37 14.57 5.7
7 −1.77 2.66 0.58 1.19 20.30 5.9
7 1.34 1.49 0.56 1.24 9.13 5.7
10 1.27 1.38 0.63 1.11 7.65 7.1
10 2.16 1.25 0.91 0.76 5.33 7.5
10 −0.25 1.55 0.51 1.36 10.32 6.3
10 −0.24 1.57 0.60 1.15 9.23 6.4
14 1.76 0.94 0.62 1.12 4.86 7.5
14 1.79 1.05 0.49 1.42 6.45 8.2
14 2.30 0.94 0.53 1.30 5.36 8.0
14 1.54 1.11 0.91 0.76 4.69 8.3
Mean 0.85 1.46 0.60 1.26 9.58 NA
STD 1.35 0.51 0.17 0.41 5.16 NA
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Extended Data Table 2
Best-fit parameters for viral dynamics following ART discontinuation.
Fitted parameters include vr, the infectious residual viral load from which the infection
starts, r, the growth rate of viral load during rebound, and vmax, the viral setpoint reached
after rebound. See the Methods section, including Equation 3, for detailed descriptions.
Fitted parameters Derived Quantities
Days until ART started log10(vr) r log10(vmax) R0 Estimated days to VL=50 copies/ml
3 −6.57 1.12 4.22 6.10 17.0
3 −0.27 0.27 4.83 1.84 16.8
3 −2.18 0.85 4.88 4.51 10.5
3 −4.34 0.80 5.22 4.20 17.5
7 0.72 0.40 4.70 2.53 5.6
7 −1.23 0.94 3.62 8.12 7.2
7 0.76 0.49 3.79 2.75 4.4
7 −0.60 0.69 5.01 3.78 7.7
10 −1.33 0.96 5.26 4.95 7.3
10 −1.17 0.89 4.00 3.74 7.4
10 1.25 0.24 5.71 1.84 4.2
10 0.12 0.38 2.50 2.24 10.1
14 1.38 0.19 3.39 1.56 3.9
14 1.23 0.36 4.22 2.34 3.0
14 1.07 0.52 4.41 3.02 2.7
14 0.24 0.51 5.00 2.37 6.6
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Figure 1. Viral decay kinetics after treatment with ART
Log plasma viral RNA (copies/ml) in rhesus monkeys infected with SIVmac251 and
following initiation of ART on days 3, 7, 10, and 14 of infection (a) or with no ART (b).
Assay sensitivity is 50 RNA copies/ml. Red arrows indicate initiation of ART. Black dots
below x-axis indicate sampling timepoints.
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Figure 2. SIV-specific humoral and cellular immune responses during ART
Env-specific ELISA antibody titers at weeks 0, 4, 10, and 24 (a) and Env-, Pol-, and Gag-
specific IFN-γ ELISPOT responses at weeks 0, 4, 10, and 20 in SIV-infected monkeys that
initiated ART on days 3, 7, 10, and 14 of infection or with no ART (b). Mean responses are
shown (N=4 animals per group). Error bars reflect standard errors.
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Figure 3. Proviral DNA during ART
Log proviral DNA (copies/106 cells) in peripheral blood mononuclear cells (PBMC), lymph
node mononuclear cells (LNMC), and gastrointestinal mucosa mononuclear cells (GMMC)
in monkeys that initiated ART on days 3 (a), 7 (b), 10 (c), and 14 (d) of infection or with no
ART (e). Comparisons of mean levels of log proviral DNA/106 cells at the time of ART
discontinuation (week 24) in ART treated and untreated (NT) monkeys in PBMC (f), LNMC
(g), and GMMC (h) are also shown (N=4 animals/group). Assay sensitivity is 3 DNA
copies/106 cells. P-values reflect one-sided t-tests. Error bars reflect standard errors.
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Figure 4. Viral rebound kinetics after ART discontinuation
Log plasma viral RNA (copies/ml) in animals following discontinuation of ART at week 24
in monkeys that initiated ART on days 3, 7, 10, and 14 of infection (a). Assay sensitivity is
50 RNA copies/ml. Median times to viral rebound, defined as the first timepoint at which
plasma viral RNA was >50 copies/ml, is also shown by the red bars (b). Median setpoint
viral loads following viral rebound, defined as day 56–112 following ART discontinuation,
are also shown by the red bars in ART treated monkeys compared with untreated monkeys
(c). P-values reflect one-sided t-tests.
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Figure 5. Viral dynamics and correlations
Correlations of area under the curve for pre-ART viral loads (AUC VL) with proviral DNA
in PBMC (a) and LNMC (b) at the time of ART discontinuation are shown. Correlations of
AUC VL (c) and proviral DNA in PBMC prior to ART discontinuation (d) with the
interpolated time to viral rebound are also shown. R2 and P-values were calculated from
correlation analyses, and trendlines were calculated using total least squares regression.
Animals with undetectable proviral DNA were plotted at the detection limit of 3 DNA
copies (0.48 log)/106 cells.
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